U.S. Veterinary Neurodegenerative Disease Diagnostics Market (2025 - 2030) Size, Share & Trends Analysis Report By Diagnostic Tests (Imaging, Biomarker Diagnostic Tests), By Animal Type (Livestock, Companion), By Product, By Indication, By End-use, And Segment Forecasts

Market Size & Trends

The U.S. veterinary neurodegenerative disease diagnostics market size was estimated at USD 105.36 million in 2024 and is expected to grow at a CAGR of 7.3% from 2025 to 2030. The key factors driving the market growth are growing research initiatives, the rising prevalence of neurodegenerative diseases, and support initiatives. The primary factor driving the market growth is the increasing number of research initiatives and projects being conducted on various species at prominent veterinary institutions across the country.

In the U.S., initiatives at institutions like the University of Wisconsin and Texas A&M University are driving significant advancements in veterinary neurodegenerative disease diagnostics. Researchers at the University of Wisconsin study late-onset peripheral neuropathy (LPN) in Labrador Retrievers to establish parallels with human hereditary peripheral neuropathies (HPNs). With NIH funding, their work includes analyzing neuromuscular junctions and developing innovative neuron cell culture models to study cellular dysfunction.

Similarly, Texas A&M and the University of Georgia are addressing Chagas disease, a zoonotic condition impacting dogs and humans. Dogs, particularly working dogs exposed to the triatomine bug, serve as crucial models in these studies. Supported by over USD 4 million, this research leverages a One Health approach, integrating field and lab investigations to better understand disease transmission and pathology. These efforts improve canine health and contribute to understanding human neuropathies.

Several factors are propelling the growth of the U.S. veterinary neurodegenerative disease diagnostics industry: the translational relevance of naturally occurring canine models, a growing recognition of the One Health concept, robust funding, and advanced molecular methodologies. By leveraging these comparative models, researchers bridge veterinary and human medicine, fostering interdisciplinary collaborations that improve diagnostics, treatments, and overall health outcomes across species.

Market Concentration & Characteristics

In the U.S. veterinary neurodegenerative disease diagnostics market, innovation is marked by integrating artificial intelligence (AI) and machine learning (ML) into diagnostic processes. For instance, researchers have developed ML algorithms to classify clinical wellness visits in cats and dogs, enhancing early disease detection. Additionally, the adoption of AI in interpreting imaging results has improved diagnostic accuracy and efficiency. These advancements contribute to more precise and timely diagnoses of neurodegenerative diseases in veterinary medicine.

Recent mergers and acquisitions significantly strengthen the market by consolidating resources, expanding service networks, and accelerating innovation. Larger, integrated veterinary care groups improve access to advanced diagnostics across more clinics, enhancing early detection and treatment of animal neurodegenerative conditions. Acquisitions by major players boost capabilities in genetic testing, point-of-care diagnostics, and pharmaceutical development, driving more precise and effective solutions. These deals foster greater collaboration, increase market efficiency, and position the U.S. as a leader in veterinary neurodegenerative disease diagnostics.

Recent U.S. regulatory updates, including the FDA's new oversight of laboratory-developed tests (LDTs) and guidance on animal genomic alterations, are strengthening the veterinary neurodegenerative disease diagnostics market. These rules ensure higher safety and consistency standards while supporting innovation through programs like the Veterinary Innovation Program. Additionally, the proposed standardization of drug labeling aims to improve clarity for veterinary diagnostics. Collectively, these regulations foster a more robust and reliable environment for developing advanced diagnostic tools.

Emerging diagnostic tools and methodologies replace traditional diagnostic approaches. The development of point-of-care (PoC) diagnostics and the integration of digital platforms have enabled more accessible and rapid testing options. These substitutes enhance diagnostic efficiency and cater to the growing demand for convenient and immediate veterinary care solutions.

U.S. veterinary diagnostics companies like Zomedica are expanding globally through strategic partnerships in Central America, the Middle East, and India. This international reach enhances their research and development by exposing them to diverse disease profiles and markets, generating additional revenue to fund innovation. It also helps achieve necessary regulatory certifications that support product quality and facilitate U.S. market approvals. Overall, global expansion drives technological advances and improves neurodegenerative disease diagnostics in the U.S. veterinary sector.

Diagnostic Tests Insights

The imaging segment held the largest market share of 45.6% in 2024. This segment consists of imaging diagnostic tests like MRI and CT scans, and their dominance can be attributed to their ability to provide detailed and high-resolution images of the brain, aiding in the detection of subtle structural changes. They help differentiate between overlapping clinical signs and are non-invasive, making them safe for repeated use. The limited availability of biomarker-based tests in veterinary practice further underscores their importance. Additionally, imaging can reveal secondary conditions mimicking neurodegenerative diseases, supporting a comprehensive evaluation. These features make them essential and a staple for accurate animal diagnosis and disease monitoring.

The biomarker diagnostic tests segment is expected to grow at the fastest CAGR of 7.7% during the forecast period. This segment comprises cerebrospinal fluid (CSF) biomarkers, blood-based biomarkers, and others such as enzyme & protein assay tests. The growth can be attributed to recent advances in identifying disease-specific CSF and blood-based biomarkers. These tests offer early detection, quantitative measures, and easy sample collection, which appeal to clinicians and pet owners. Blood-based biomarkers, in particular, are minimally invasive compared to brain imaging. This trend is driven by increasing awareness of cognitive health in aging pets and the need for objective, early-stage diagnostic tools. These factors collectively position biomarker tests as crucial to the evolving veterinary neurology landscape.

Animal Type Insights

The companion animal segment dominated the U.S. veterinary neurodegenerative disease diagnostics industry in 2024 and is also expected to grow at the fastest CAGR over the forecast period. This segment, which includes animals such as canines, felines, equines, etc., is mainly driven by rising pet ownership and increased awareness of neurodegenerative conditions like degenerative myelopathy in dogs, cerebellar abiotrophy in horses, and canine cognitive dysfunction.

Enhanced diagnostic capabilities, including genetic screening and MRI imaging, fuel demand. Strong emotional bonds between owners and their pets encourage investment in advanced care. Significant R&D investments from academic, biotech, and federal sources are focusing on developing innovative imaging, genetic, and biomarker tools for companion animals.

Product Insights

The consumables, reagents, and kits segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period. This dominance can be attributed to their essential role in routine testing, offering veterinarians cost-effective, convenient, and standardized solutions. These products are frequently used in genetic screening, biomarker assays, and immunoassays and are key tools for diagnosing conditions like canine cognitive dysfunction.

With over 94 million pet-owning households in the U.S., high testing volumes drive repeat purchases of these consumables, unlike larger capital equipment, which is more of a one-time investment. Additionally, consumables enable faster turnaround times, which is crucial in clinical settings where speed is valued. The growth of pet insurance coverage and a pet owner's willingness to invest in advanced care fuel demand for these accessible and scalable testing solutions.

Indication Insights

The cognitive dysfunction segment held the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period. In the U.S., these diagnostic tests are most commonly conducted for cognitive dysfunction syndrome (CDS) primarily because it is highly prevalent among aging companion animals, especially dogs and cats, constituting the largest segment of pet ownership. With over 68 million dogs and 49 million cats in U.S. households, awareness of age-related cognitive decline has grown substantially. Owners more easily observe CDS symptoms, prompting veterinary visits and diagnostic evaluations. In contrast, conditions like cerebellar abiotrophy and spongiform encephalopathies are far rarer and often breed-specific or have limited geographic incidence, reducing demand for routine testing.

Additionally, CDS benefits from established diagnostic criteria and non-invasive tools, such as behavioral assessments and advanced imaging, making testing more accessible. Federal and academic funding also prioritize research into CDS due to its growing impact on companion animal welfare. At the same time, prion diseases like spongiform encephalopathies are sporadic and have minimal incidence in U.S. pets. The combination of high prevalence, owner awareness, accessible diagnostics, and research focus explains why CDS dominates neurodegenerative testing in U.S. veterinary practice.

End-use Insights

Veterinary hospitals and clinics dominate the veterinary neurodegenerative disease diagnostics sector because they serve as the primary point of care for pets with neurological symptoms. They offer integrated diagnostic services alongside clinical evaluations, enabling rapid and personalized treatment decisions. Unlike specialized labs that process specific tests, clinics provide comprehensive, on-site solutions, enhancing convenience for pet owners. Many hospitals also invest in advanced imaging equipment, such as MRI and CT scanners, strengthening in-house diagnostic capabilities and reducing turnaround times. This seamless integration of services and technology drives higher demand for neurodegenerative disease diagnostics within these settings.

The veterinary diagnostic laboratories segment is expected to grow at the fastest CAGR of around 8% during the forecast period. This can be owed to rising awareness of animal neurological diseases and the need for accurate diagnoses. These labs have expanded their capabilities to include advanced biomarker assays, molecular diagnostics, and histopathology for early and precise detection. They leverage cutting-edge technologies like next-generation sequencing, AI-driven imaging analysis, and metabolomics to offer comprehensive testing. Integration with veterinary practices through digital platforms enhances convenience and adoption. Regulatory compliance and research collaborations ensure high-quality diagnostics and foster innovation. Consequently, these labs are driving the growth of the neurodegenerative diagnostics sector in veterinary medicine.

Key U.S. Veterinary Neurodegenerative Disease Diagnostics Company Insights

The U.S. veterinary neurodegenerative disease diagnostics market is experiencing moderate competition, driven by a blend of established players and innovative newcomers. Technological advancements and a growing recognition of animal neurological conditions fuel the demand for sophisticated diagnostic solutions. Major companies are pursuing mergers, partnerships, and new product launches to expand their offerings and meet evolving customer needs. Furthermore, numerous research projects on neurodegenerative biomarkers and novel testing methods contribute to rapid market evolution. As a result, the sector is poised for sustained growth and innovation, emphasizing precision diagnostics and early disease detection.

Recent Developments

• In April 2025, scientists at the Wisconsin-Madison School of Veterinary Medicine are investigating Labrador Retrievers with late-onset peripheral neuropathy (LPN), commonly known as laryngeal paralysis, to understand hereditary peripheral neuropathy (HPN) in humans. Their study aims to establish LPN as a canine model for human axonal HPNs by examining neuromuscular junctions and peripheral nerves and identifying genetic variants contributing to axonal degeneration. This research can potentially develop treatments applicable to both dogs and humans.

• In August 2024, researchers at the University of Minnesota developed Cap-QuIC (Capillary-enhanced Quaking-Induced Conversion), a visual diagnostic technique enabling the early detection of neurodegenerative diseases like Parkinson's and Chronic Wasting Disease in animals like deer. This method allows for distinguishing infected samples with the naked eye, making testing more accessible and cost-effective.

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Report Scope

U.S. Veterinary Neurodegenerative Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the U.S. veterinary neurodegenerative disease diagnostics market report based on animal type, product, diagnostic test, indication, and end use:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Consumables, Reagents & Kits

  • Equipment & Instruments

• Diagnostic Tests Outlook (Revenue, USD Million, 2018 - 2030)

  • Imaging

    • MRI (Magnetic Resonance Imaging)

    • CT (Computed Tomography)

    • Others

  • Biomarker Diagnostic Tests

    • CSF (Cerebrospinal Fluid) biomarkers

    • Blood-based biomarkers

    • Others

  • Others

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Livestock

    • Sheep

    • Cattle

    • Others

  • Companion

    • Canine

    • Feline

    • Equine

    • Others

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Cognitive Dysfunction

  • Cerebellar Abiotrophy

  • Spongiform Encephalopathies

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Veterinary Hospitals and Clinics

  • Veterinary Diagnostic Laboratories

  • Others